SPRB
Spruce Biosciences, Inc.NASDAQHealthcare$70.50+1.39%ClosedMarket Cap: $40.9M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.14
P/S
0.00
EV/EBITDA
0.33
DCF Value
$61.82
FCF Yield
-91.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-204.0%
ROA
-73.5%
ROIC
-84.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-11.1M | $-14.6M | $-10.67 | — |
| FY 2025 | $0.00 | -Infinity% | $-36.5M | $-39.0M | $-50.83 | — |
| Q3 2025 | $0.00 | NaN% | $-8.2M | $-8.2M | $-14.58 | — |
| Q2 2025 | $0.00 | NaN% | $-2.7M | $-2.1M | $-3.41 | — |
| Q1 2025 | $0.00 | NaN% | $-14.5M | $-14.0M | $-24.00 | — |
| Q4 2024 | $697.0K | 100.0% | $-24.1M | $-23.6M | $-43.50 | — |
| FY 2024 | $4.9M | 100.0% | $-56.2M | $-53.0M | $-96.75 | — |
| Q3 2024 | $602.0K | 100.0% | $-9.4M | $-8.7M | $-16.50 | — |
| Q2 2024 | $1.6M | 100.0% | $-10.0M | $-9.2M | $-16.50 | — |
| Q1 2024 | $2.0M | 100.0% | $-12.6M | $-11.6M | $-21.00 | — |
| Q4 2023 | $2.9M | 99.4% | $-11.2M | $-9.9M | $-18.00 | — |
| FY 2023 | $10.1M | 100.0% | $-52.0M | $-47.9M | $-93.00 | — |